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Background: Liver transplantation is a challenging procedure that is associated with perioperative morbidity and mortality,
so it is justifiable to perform such a procedure in high-volume procedure centers. Organ shortage remains a major issue
in Taiwan. Due to the difficulty in establishing a high-volume procedure center, it is important to review the overall outcome
of patients undergoing liver transplantation at a small-volume procedure center to determine if performing such a procedure
is justified.
Methods: Between April 2001 and May 2005, 26 adults underwent deceased donor liver transplantation at Taipei Veterans
General Hospital. The overall outcomes were reviewed in terms of 90-day mortality, 1-year and 3-year survival rates. 
In addition, the patients were divided into a hepatocellular carcinoma (HCC) group (n = 12) and a benign end-stage liver
disease (ESLD) group (n = 14). The clinical demographics, 90-day mortality, 1-year and 3-year survival rates were
reviewed and compared between the 2 groups.
Results: The 90-day mortality was 15.3% in the whole series, 8.3% in the HCC group and 18.7% in the ESLD group. The
overall 1-year and 3-year survival rates were 76.9% and 63.5%, respectively, for the whole series. For the 2 groups, the
respective 1-year and 3-year survival rates were 83.3% and 71.4% in the HCC group, and 71.4% and 57.1% in the ESLD
group. The survival difference was not significant (p = 0.319) between the 2 groups. In the HCC group, the 1-year and 3-year
disease-free survival rates were 88.9% and 71.1%, respectively.
Conclusion: The survival rates between ESLD and HCC patients undergoing liver transplantation at a small-volume procedure
center were comparable. The results of the whole series were not satisfactory, but the results for the HCC group were
acceptable. [J Chin Med Assoc 2008;71(4):186–190]
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Introduction
The first human liver transplantation was performed
in 1963, but poor initial results kept liver transplanta-
tion an experimental surgery for 20 years before it was
accepted as a definitive therapeutic modality for end-
stage liver disease (ESLD).1 Because of the challenging
procedure and high perioperative mortality associated
with liver transplantation, it has been suggested that
this procedure be done in centers with a high volume of
procedures to ensure better patient outcome.2 Organ
shortage has long been a significant problem faced 
by the transplant society, and because of folk beliefs
and religions, organ shortage is generally more severe
in Asian countries compared with Western ones. The
organ donation rate is about 4.7 per million people
per year in Taiwan.3 This number is far behind that in
Spain, a country with an organ donation rate of around
24.1 per million people per year.4 Therefore, it is dif-
ficult to establish a center with a high volume of liver
transplants in Taiwan. Under these circumstances, we
wanted to review the overall outcome of patients who
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underwent liver transplantations at a small-volume pro-
cedure center to determine if it is justifiable to per-
form liver transplantations at such a center. In addition,
subgroup analysis was done to compare the outcome
between patients with benign ESLD and patients with
hepatocellular carcinoma (HCC).
Methods
The study complied with current ethical guidelines of
medical research. Between April 2001 and May 2005,
26 adults underwent deceased donor liver transplan-
tation (DDLT) at Taipei Veterans General Hospital
(TVGH). There were 17 males and 9 females. The mean
age of these patients was 54.0±10.7 years (range, 24–68
years). Nineteen patients had chronic hepatitis B virus
(HBV) infection, 3 had chronic hepatitis C virus (HCV)
infection, 2 had Wilson’s disease, 1 was an alcoholic,
and 1 had cryptogenic liver cirrhosis.
Model of end-stage liver disease (MELD) score was
introduced into Taiwan’s organ allocation system in
2004. Before 2004, waiting time had been a priority
for organ allocation except for urgency. Mean MELD
score of the subjects in this study was 14.9 ± 7.6 (range,
6–42). Among the 26 patients, 12 had concomitant
HCC preoperatively (Table 1). All of the HCC patients
included in this study met the Milan criteria5 before
transplantation.
All patients underwent orthotopic liver transplan-
tation without venous-venous bypass. The immunosup-
pressant regimen consisted of intraoperative induction
of methylprednisolone 1g and then tapering to oral pred-
nisolone 20 mg on the 7th postoperative day. Steroid
was withdrawn before 6 months after transplantation.
The main maintenance immunosuppressant was tacro-
limus (Astellas Pharma, Osaka, Japan). The dosage of
tacrolimus was 0.025–0.15 mg/kg/day in 2 divided
doses. The trough blood level was kept between
2.5 ng/mL and 20 ng/mL.
The patients’ clinical demographic data, operative
mortality and pathologic results were reviewed. Opera-
tive mortality was defined as death within 30 days 
of transplantation or during the same period of hos-
pitalization. The median follow-up time was 25.3
months (mean, 28.8 ± 10.7 months; range, 1 day to
69.3 months). The patients’ overall survival rate was
calculated using the Kaplan-Meier method. In addition,
patients were further divided into an HCC group
(n = 12) and an ESLD group (n = 14). The clinical
demographic characteristics, surgical outcomes and sur-
vival rates were compared between the 2 groups. Con-
tinuous variables were compared using Student’s t test,
and categorical variables were compared using Fisher’s
exact test. The difference in survival between the HCC
and ESLD groups was calculated using log-rank test.
Results
In this series, 4 patients died within 30 days of trans-
plantation. The causes of mortality in 1 patient each
were hemorrhagic shock, small-for-size syndrome, por-
tal vein thrombosis, and intracranial hemorrhage. Oper-
ative mortality was 15.3% (4/26). The overall 1-year
and 3-year survival rates for the whole series were 76.9%
and 63.5%, respectively (Figure 1).
Table 1. Demographic characteristics of 26 adult patients who
underwent deceased donor liver transplantation between April
2001 and May 2005 at Taipei Veterans General Hospital
Age (yr) 54.0 ± 10.7
Male/female (n) 17/9
MELD score 14.9 ± 7.6
ESLD/HCC 14/12
Etiology (n)
HBV 19
HCV 3
Wilson’s disease 2
Alcoholism 1
Cryptogenic liver cirrhosis 1
Median follow-up (mo) 25.3
MELD = model of end-stage liver disease; ESLD = end-stage liver disease;
HCC = hepatocellular carcinoma; HBV = hepatitis B virus; HCV = hepatitis 
C virus.
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Figure 1. Survival curves for the total number of patients and
patients in the end-stage liver disease (ESLD) and hepatocellular
carcinoma (HCC) groups.
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The male-to-female ratio in the HCC group was 
8 to 4, while it was 9 to 5 in the ESLD group (p=1.000).
The mean age in the HCC group was 58.5 ± 6.6 years,
while it was 50.14 ± 12.2 years in the ESLD group
(p=0.039). There was no significant difference in MELD
score between the HCC and ESLD groups (13.33±4.9
vs. 16.21±9.2, p=0.343). Operative mortality was 8.3%
(1/12) in the HCC patients and 18.7% (3/16) in the
ESLD patients (Table 2). The 1-year survival rates for
the HCC patients and ESLD patients were 83.3% and
71.4%, respectively. The 3-year overall survival rates
for the HCC patients and ESLD patients were 71.4%
and 57.1% (p = 0.319), respectively (Figure 1).
In the HCC group, 1 patient died as a result of
post-transplantation intracranial bleeding on post-
operative day 9, and 2 died of sepsis, at 5 months and
31 months after transplantation, respectively, without
evidence of tumor recurrence (Table 3). In the ESLD
group, 6 patients died: 3 were due to surgical compli-
cations, and 1 each to hemorrhagic shock, portal vein
thrombosis and small-for-size syndrome on postoper-
ative days 1, 3 and 7, respectively. The diagnosis of small-
for-size syndrome was made according to the patient’s
clinical presentations of progressive hyperbilirubinemia
without mechanical cause and refractory ascites in 
the absence of vascular complications within 7 days of
liver transplantation. Another 3 patients died of suf-
focation, sepsis, and suicide, at 7, 13 and 17 months
after transplantation, respectively (Table 4). Of the 12
HCC patients, 9 had received pre-transplant treatment
(1 surgical resection, 1 surgical resection for primary
tumor and transarterial embolization for recurrence,
7 locoregional ablative therapies). During the post-
transplantation follow-up period, 2 patients were found
to have recurrent tumors. One of the 2 patients had
intrahepatic recurrence, peritoneal seeding, and lung
and spleen metastases at 23 months after transplanta-
tion. The other patient had tumor in the liver, lung and
brain at 32 months after transplantation. The recur-
rence rate was 16.7% (2/12). The 1-year disease-free
survival rate was 88.8%, and the 3-year disease-free
survival rate was 71.1% (Figure 2).
Discussion
Liver transplantation had been an experimental surgery
until 1983, 20 years after the first human liver transplant,
Table 2. Clinical demographic characteristics of patients with hepatocellular carcinoma (HCC) and patients with end-stage liver disease
(ESLD) who underwent deceased donor liver transplantation
HCC group ESLD group p
Male/female (n) 8/4 9/5 1.000
Age (yr) 58.5 ± 6.6 50.14 ± 12.2 0.039
MELD score 13.33 ± 4.9 16.21 ± 9.2 0.343
Operative mortality (n) 1/12 3/14 0.613
MELD = model of end-stage liver disease.
Table 3. Clinical demographic characteristics and outcome of patients with hepatocellular carcinoma who underwent deceased donor
liver transplantation
Patient Age (yr) Gender Etiology MELD score Status Follow-up (mo) Time to recurrence (mo) COD
1 67 Female HBV 9 Alive 69 – –
2 66 Male HCV 10 Alive 60 – –
3 57 Male HBV 14 Alive 51 – –
4 57 Male HCV 6 Dead 32 – Sepsis
5 45 Male HBV 15 Alive 46 – –
6 66 Female HBV 21 Dead 5 – Sepsis
7 55 Male HBV 11 Alive 33 23* –
8 52 Male HBV 16 Alive 33 32† –
9 57 Male HBV 8 Alive 25 – –
10 62 Female HBV 22 Alive 23 – –
11 55 Male HBV 13 Alive 22 – –
12 63 Female HCV 15 Dead POD9 – ICH
*Intrahepatic recurrence, peritoneal seeding, lung and spleen metastases; †liver, lung and brain metastases. MELD = model of end-stage liver disease; COD =
cause of death; HBV = hepatitis B virus; HCV = hepatitis C virus; POD = postoperative day; ICH = intracranial hemorrhage.
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when experts at the Consensus and Development
Conference of the National Institute of Health rec-
ommended that liver transplantation be a definitive
treatment for ESLD.1 The first successful human liver
transplantation in Asia was performed in Taiwan by
Chen et al in 1984.6 Their successful operation influ-
enced the development of liver transplantation not only
in Taiwan but also in other Asian countries. Soon after
the first liver transplantation in Asia, the first liver trans-
plantation at TVGH was performed, on March 31,
1985. However, no patient survived for more than 
1 year until 1990. Before 2001, there were only 14 liver
transplantations done at TVGH over a 16-year period.
The learning process has been long and slow. Between
January 2001 and December 2005, a total of 33 DDLTs
were performed at TVGH, with 14 of the 33 transplants
done in 2005. However, by definition, TVGH is still
a small-volume center for DDLT.2
In spite of an increased number of organ donations
in Taiwan during the past decade, there were only 73
liver grafts available from deceased donors in 2005.3
Under such circumstances, it is difficult to establish a
high-volume procedure center in Taiwan. Hence, it is
necessary to review the results of a small-volume pro-
cedure center to see if it is justifiable to perform liver
transplantation.
According to the report of Edwards et al,2 the 90-
day mortality rate at low-volume centers was 20.9%,
while it was 14.1% at high-volume centers (> 20
procedures/year). The 1-year mortality rate at low-
volume centers ranged from 25.9% to 29.9%, and from
20.0% to 25.1% at high-volume centers, according to
the different time periods. In our series, the 90-day mor-
tality rate was 15.3%, and the 1-year mortality rate was
23.1%. These results are comparable to those of high-
volume centers reported by Edwards et al.2
It is generally accepted that the 1-year survival rate
is 80% and the 3-year survival rate is 75% for ESLD
patients undergoing liver transplantation. Our series
showed that ESLD patients undergoing liver trans-
plantation achieved a 1-year survival rate of 71.4% and
a 3-year survival rate of 57.1%. These results are not
satisfactory. The reason for the unsatisfactory outcome
was mainly due to 3 of the 6 cases of mortality occurring
within 30 days after transplantation. The mean MELD
score in our patients was 14.9 ± 7.6, which means that
most of our patients were not critically ill. Refinement
Table 4. Clinical demographic characteristics and outcome of patients with end-stage liver disease who underwent deceased donor
liver transplantation
Patient Age (yr) Gender Etiology MELD score Status Follow-up (mo) COD
1 44 Male Wilson’s disease 11 Dead 13 Sepsis
2 37 Male HBV 26 Dead POD1 Hemorrhagic shock
3 56 Male HBV 17 Alive 64 –
4 68 Female Cryptogenic liver cirrhosis 23 Dead 7 Suffocation
5 62 Male HBV 8 Alive 55 –
6 47 Female HBV 11 Dead 17 Suicide
7 58 Female HBV 16 Alive 43 –
8 24 Male HBV 8 Dead POD7 Small-for-size syndrome
9 46 Male Alcoholism 13 Alive 36 –
10 63 Male HBV 19 Dead POD3 Portal vein thrombosis
11 37 Female Wilson’s disease 8 Alive 32 –
12 47 Male HBV 13 Alive 26 –
13 63 Male HBV 42 Alive 23 –
14 60 Female HBV 12 Alive 20 –
MELD = model of end-stage liver disease; COD = cause of death; HBV = hepatitis B virus; POD = postoperative day.
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Figure 2. Disease-free survival curve of 12 adults with hepato-
cellular carcinoma (HCC) who underwent deceased donor liver
transplantation.
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of perioperative care and surgical techniques should
decrease surgical mortality and improve patient survival.
Liver transplantation is justified for patients with
liver malignancy only when the outcome after trans-
plantation is comparable to that of patients with ESLD,
especially in a country with organ shortages. The prog-
nosis of patients with HCC undergoing liver transplan-
tation in the initial series was disappointing. Even in the
early 1990s, the 5-year survival rate was 15–48%.7–10
The tumor recurrence rate was up to 54%.9 The poor
outcome was mainly due to unrestrictive patient selec-
tion criteria. In the late 1990s, the survival rate of HCC
patients undergoing liver transplantation improved
greatly. The most notable result was from the Milan
group. In 1996, Mazzaferro et al5 demonstrated that
HCC patients with a single tumor no larger than 5 cm,
or with no more than 3 tumors with each tumor being
no larger than 3 cm, could achieve a 1-year survival rate
of 90% and a 3-year survival rate of 76%. The overall
recurrence rate was 8%, and the 4-year disease-free sur-
vival rate was 83%. These selection criteria were called
the Milan criteria. With restrictive patient selection
criteria, these satisfactory outcomes were reproducible
in other later series.11–13
In Taiwan, we follow the Milan criteria for patients
with HCC undergoing DDLT. In this series, 12 patients
with HCC underwent liver transplantation. Our results
showed that the 1-year and 3-year overall survival rates
were 83.3% and 71.4%, respectively; 1-year and 3-year
disease-free survival rates were 88.9% and 71.1%, re-
spectively. The figures were better than those for our
patients with ESLD, although the difference was not
statistically significant (p=0.319). The outcome was also
comparable to results from other larger series.5,11–13
The preliminary results of this whole series were
not satisfactory but they were acceptable, especially for
the HCC group. The results indicate that liver trans-
plantation at a center with a small volume of proce-
dures in Taiwan is justifiable, but there remains much
room for further improvement.
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